Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo that grants Senzime the rights to use some of Masimo's intellectual property; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
Frequently asked questions
What sector does Senzime AB (SEZI) operate in?
Senzime AB belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Senzime AB (SEZI) current stock price?
As of the latest data, Senzime AB stock price is SEK 4.00, with a previous close of SEK 3.93. Senzime AB gained SEK 0.07 in the last trading session, representing a 1.78% increase.
What is Senzime AB (SEZI) current market capitalization?
Senzime AB market cap is approximately 628.07 million.
What is Senzime AB (SEZI) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.71, and the forward EPS is -SEK 0.10.
What is Senzime AB (SEZI) EBITDA?
Senzime AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.92 million.
Does Senzime AB (SEZI) pay dividends?
No. Senzime AB does not pay a dividend.
When is Senzime AB (SEZI) next earnings report?
Senzime AB is expected to release its next earnings report on September 30, 2026.
What is Senzime AB (SEZI) beta (volatility) score?
Senzime AB has a beta of 0.389, indicating lower volatility than the overall market.
